2020
Prognostic and Predictive Biomarkers in Oligometastatic Disease.
Barnum KJ, Weiss SA. Prognostic and Predictive Biomarkers in Oligometastatic Disease. The Cancer Journal 2020, 26: 100-107. PMID: 32205533, PMCID: PMC9208067, DOI: 10.1097/ppo.0000000000000438.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCirculating Tumor DNAClinical Decision-MakingDisease-Free SurvivalHumansMicroRNAsMutationNeoplasmsNeoplastic Cells, CirculatingPatient SelectionPrognosisProgression-Free SurvivalRadiofrequency AblationRadiosurgeryRisk AssessmentSurvival RateConceptsLocal therapyOligometastatic diseaseSystemic therapyPredictive biomarkersCurative-intent local therapyAdvanced disease stateCancer-related deathSurvival benefitPatient candidatesMetastatic lesionsPatient selectionPoor prognosisAblative treatmentClinical definitionTumor biologyTherapyOligometastasesDisease statesDiseasePatientsLocal interventionsBiomarkersPolymetastasesPrognosisLesions
2016
Chapter 20 Management of Melanoma Therapy-Associated Toxicities
Weiss S, Kavecansky J, Pavlick A. Chapter 20 Management of Melanoma Therapy-Associated Toxicities. 2016, 299-319. DOI: 10.1016/b978-0-12-803508-5.00020-2.Peer-Reviewed Original ResearchSkin cancer-related deathsAntitumor immune responseUnique adverse eventsCancer-related deathPatient survival outcomesNew therapeutic strategiesQuality of lifeMelanoma driver mutationsChapter 20 ManagementAdverse eventsAdvanced melanomaSurvival outcomesImmune responseTherapeutic strategiesInitial approvalAggressive natureSkin cancerNew casesPatient safetyDriver mutationsMelanomaSignificant delayTherapyCliniciansVast majority